Evaluation of varenicline as an aid to smoking cessation in UK general practice a THIN database study

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 861-870

  Blak, Betina T ^a   Wilson, Koo ^b   Metcalfe, Michael ^b   Maguire, Andrew ^c   Hards, Michelle ^a  

^a EPIC   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

4 2 nicotinic acetylcholine receptor partial agonist; Compliance; Effectiveness; Smoking cessation; UK general practice; Varenicline

Indexed keywords

NICOTINE; PLACEBO; VARENICLINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PREVALENCE; QUESTIONNAIRE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM;

BENZAZEPINES; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; NICOTINIC AGONISTS; PREVALENCE; QUINOXALINES; RETROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION;

EID: 77949517326     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903526461     Document Type: Article

References (19)

1. Russell MA, Feyerabend C. Cigarette smoking: a dependence on high nicotine boli. Drug Metabol Rev 1978;8:29-57
2. The Tobacco Advisory Group of the Royal College of Physicians. Nicotine addiction in Britain. London: The Royal College of Physicians 2000. Available at: http://www.rcplondon.ac.uk/pubs/wp/wp-nicotine-summary. htm#contents [Last accessed 25 November 2009]
3. Cigarette smoking. A slight fall in smoking prevalence. Office for National Statistics, UK, 2006. Available at: http://www.statistics.gov.uk/cci/ nugget. asp?id = 866 [Last accessed 5 November 2009]
4. Cahill K, Stead L, Lancaster TA. Preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009;32:119-135
5. Edwards R. The problem of tobacco smoking. Br Med J 2004;328:217-219
6. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38
7. PH10 Smoking cessation services: guidance. National Institute for Health and Clinical Excellence (NICE) 2008. Available at: http://guidance.nice.org.uk/ PH10/NiceGuidance/pdf/English [Last accessed 25 November 2009]
8. EPARs for authorised medicinal products for human use: Champix. European Medicines Agency 2009. Available at: http://www.emea.europa. eu/humandocs/Humans/EPAR/champix/champix.htm [Last accessed 4 November 2009]
9. Lam S, Patel PN. Varenicline: a selective a4j62nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev 2007;15: 154-161
10. British National Formulary (BNF) 58. British Medical Association and Royal Pharmaceutical Society of Great Britain. London, 2009
11. Gonzales, D, Rennard, SI, Nides M, et al. Varenicline, an a4fi2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. J Am Med Assoc 2006;296:47-55
12. Jorenby DE, Hays TJ, Rigotti NA, et al. Efficacy of varenicline, an a4fi2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. J Am Med Assoc 2006;296:56-63
13. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296:64-71
14. Stapleton JA, Watson L, Spirling L, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103:146-154
15. Ramon JM, Bruguera I. Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Publ Health 2009;6:1530-1538
16. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401
17. Blak BT, Hsia Y, Hards M. Deprivation and prevalence of risk factors and chronic diseases-is there a trend? Pharmacoepidemiol Drug Saf 2009;18(S1):S224
18. Keeler TE, Marciniak M, Hu TW. Rational addiction and smoking cessation: an empirical study. J Soc Econ 1999;28:633-643
19. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009;32:499-507